Scalper1 News
Over the last two years, hepatitis C has produced the most epic drug launches in history. But as the fanfare dies down, investors face a key question: How much longer can this drug pipeline pop? The question is grounded in the sheer success of the existing treatments. Gilead Sciences’ (GILD) Sovaldi and Harvoni and AbbVie’s (ABBV) Viekira Pak have been curing well over 90% of the patients who take them for a few months, and in the U.S. the Scalper1 News
Scalper1 News